Skip to main content
Signal8
Launch Terminal

Tango Therapeutics, Inc. (TNGX)

Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc.

NASDAQ:TNGXHealthcare
+0.84%$22.72
AH$22.72+0.00%vs close
Mkt Cap$3.83B
Float140.42M
O/S168.61M
Vol
$ Vol
RVOL
Inst Own-
SI31.9%
Earnings
Dilution
Tango Therapeutics, Inc. logoNASDAQ:TNGX$22.72+0.84%
Upcoming Catalysts
Phase Distribution
7 lead-sponsored trials·4 active·0 completed
Phase 1/27
(1 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
  • Phase 1/2
    Terminated

    Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

    TNG908

    Locally Advanced Solid Tumor

    Enrollment
    110
    Start
    Mar 2022
    Primary Completion
    Dec 2025
    Completion
    Dec 2025
    NCT05275478
  • Phase 1/2
    Recruiting

    Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

    TNG462, Pembrolizumab

    Locally Advanced Solid Tumor

    Enrollment
    225
    Start
    May 2023
    Primary Completion
    Jun 2027est.
    Completion
    Jun 2028est.
    NCT05732831
  • Phase 1/2
    Active, not recruiting

    Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

    TNG260, Pembrolizumab

    Non Small Cell Lung Cancer, Solid Tumors, Adult +2

    Enrollment
    126
    Start
    Jun 2023
    Primary Completion
    Sep 2026est.
    Completion
    Sep 2026est.
    NCT05887492
  • Phase 1/2
    Terminated

    Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

    TNG348, Olaparib

    Breast Cancer, Ovarian Cancer +6

    Enrollment
    7
    Start
    Dec 2023
    Primary Completion
    May 2024
    Completion
    May 2024
    NCT06065059
  • Phase 1/2
    Recruiting

    Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

    TNG456, abemaciclib

    Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme +5

    Enrollment
    191
    Start
    Mar 2025
    Primary Completion
    Mar 2027est.
    Completion
    Sep 2027est.
    NCT06810544
  • Phase 1/2
    Recruiting

    Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

    TNG462, RMC-9805

    PDAC, PDAC - Pancreatic Ductal Adenocarcinoma +6

    Enrollment
    183
    Start
    May 2025
    Primary Completion
    Jun 2027est.READOUT
    Completion
    Dec 2027est.
    NCT06922591
  • Phase 1/2
    Not yet recruiting

    TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients

    vopimetostat, ERAS-0015

    PDAC, PDAC - Pancreatic Ductal Adenocarcinoma +6

    Enrollment
    188
    Start
    Nov 2026est.
    Primary Completion
    Nov 2031est.
    Completion
    May 2032est.
    NCT07897734
Search ClinicalTrials.gov for “Tango Therapeutics”